The Enterprise Value as of January 2025 (TTM) for CymaBay Therapeutics, Inc. (CBAY) is 3.64B

According to CymaBay Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.64B. This represents a change of 139.83% compared to the average of 1.52B of the last 4 quarters.

CymaBay Therapeutics, Inc. (CBAY) Historical Enterprise Value (quarterly & annually)

How has CBAY Enterprise Value performed in the past?

The mean historical Enterprise Value of CymaBay Therapeutics, Inc. over the last ten years is 457.48M. The current 3.64B Enterprise Value has changed 79.38% with respect to the historical average. Over the past ten years (40 quarters), CBAY's Enterprise Value was at its highest in in the December 2023 quarter at 2.58B. The Enterprise Value was at its lowest in in the March 2016 quarter at 19.88M.

CymaBay Therapeutics, Inc. (CBAY) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of CymaBay Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CymaBay Therapeutics, Inc. (CBAY) Average Enterprise Value

How has CBAY Enterprise Value performed in the past?

The current Enterprise Value of CymaBay Therapeutics, Inc. (CBAY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

CymaBay Therapeutics, Inc. (CBAY) Enterprise Value vs. Peers

How is CBAY’s Enterprise Value compared to its peers?

CymaBay Therapeutics, Inc.’s Enterprise Value is greater than Day One Biopharmaceuticals, Inc. (705.29M), greater than X4 Pharmaceuticals, Inc. (58.53M), greater than Inozyme Pharma, Inc. (119.22M), greater than Acumen Pharmaceuticals, Inc. (90.53M), greater than Mereo BioPharma Group plc (394.10M), greater than Akero Therapeutics, Inc. (1.25B), greater than Terns Pharmaceuticals, Inc. (119.34M), less than Madrigal Pharmaceuticals, Inc. (5.87B), less than Viking Therapeutics, Inc. (3.73B), greater than Biomea Fusion, Inc. (72.01M), greater than Stoke Therapeutics, Inc. (312.04M), greater than Homology Medicines, Inc. (-103303255.00), greater than Gossamer Bio, Inc. (367.41M), greater than 89bio, Inc. (684.57M), greater than Pliant Therapeutics, Inc. (664.59M), greater than Arcellx, Inc. (3.40B), greater than Kiniksa Pharmaceuticals, Ltd. (1.24B), greater than Structure Therapeutics Inc. (1.29B), less than Karuna Therapeutics, Inc. (12.43B), greater than Phathom Pharmaceuticals, Inc. (306.01M),

Build a custom stock screener for CymaBay Therapeutics, Inc. (CBAY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CymaBay Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CymaBay Therapeutics, Inc. (CBAY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CymaBay Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.